Filter Releases
 
Press Releases
Date Title and Summary View
Dec 15, 2017
WALTHAM, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS)  announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), will issue a third Day-180 List of Outstanding Issues. As part of its on-going risk-benefit assessment, the CHMP ...
Dec 11, 2017
WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that Fractured Truth—an unbranded patient campaign aimed to educate younger postmenopausal women about risks associated with osteoporosis—won the Bronze Healthcare/Pharmaceutical Industry Pearl Award at the Content ...
Dec 7, 2017
-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017- -Median PFS was 5.4 months and Clinical Benefit Rate at 24 weeks was 47.4% - ...
Dec 4, 2017
SABCS to include five abstracts from the development program for elacestrant as a potential treatment of ER-positive advanced breast cancer Radius to host live webcast to discuss data presented at SABCS and provide a company update on December 7th at 8:00 p.m. CT / 9:00 p.m...
Nov 27, 2017
WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced that its Board of Directors granted Joseph Kelly, in connection with his appointment as the Company's Senior Vice President of Sales and Marketing, an option to purchase 60,000 shares of the Company's c...
Nov 27, 2017
WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to Senior Vice President of Market Access. Mr. Kelly succeeds David Snow who served as t...
Nov 2, 2017
First full quarter of TYMLOS™ sales shows accelerating market share & stabilization of the anabolic market Plan access at approximately 200 million lives — 87% commercial and 35% Medicare Male Osteo Trial: FDA agre­ement on the design of a clinical trial in men ...
Oct 18, 2017
- Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018 - - Phase 2 Study is a potentially pivotal trial for accelerated approval - WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSW...
Oct 13, 2017
Five posters will cover new data on the need for osteoporosis awareness as well as cost-effectiveness data on treatment with TYMLOS WALTHAM, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing and commercializing innovat...
Oct 9, 2017
WALTHAM, Mass., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update....
Sep 29, 2017
WALTHAM, Mass., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that the first patient has been enrolled in the company's Phase 1 study of RAD140, a nonsteroidal selective androgen receptor modulator (SARM) undergoing clinical evaluation for the treatment of hormone receptor positive breast c...
Sep 22, 2017
WALTHAM, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that Jesper Høiland, Pre...
Sep 10, 2017
ACTIVExtend trial demonstrated statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by alendronate WALTHAM, Mass., Sept. 10, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing a...
Sep 7, 2017
WALTHAM, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that Jesper Høiland, ...
Sep 1, 2017
Results from the ACTIVExtend trial, which demonstrated statistically significant fracture risk reduction at 3.5 years of sequential therapy — TYMLOS followed by alendronate — will be presented in an Oral Plenary Session            Company plans to submit the ACTIVExt...
Page:
...
Next Last
 
= add release to Briefcase